Alterity Therapeutics Limited [NASDAQ: ATHE] stock went on a downward path that fall over -11.54% on Thursday, amounting to a one-week price increase of more than 2.22%. The company report on August 4, 2021 that Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s.
Composition of Matter Patent Covers More than 80 Novel Compounds.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Alterity’s patent application No. 17/239,375. The composition of matter patent secures exclusivity for a new group of iron chaperones designed to redistribute the excess iron implicated in many neurodegenerative diseases, including Alzheimer’s and Parkinson’s.
Over the last 12 months, ATHE stock dropped by -9.80%.
The market cap for the stock reached $60.76 million, with 22.06 million shares outstanding and 20.81 million shares in the current float. Compared to the average trading volume of 6.54M shares, ATHE stock reached a trading volume of 2891212 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Alterity Therapeutics Limited [ATHE]:
The Average True Range (ATR) for Alterity Therapeutics Limited is set at 0.19, with the Price to Sales ratio for ATHE stock in the period of the last 12 months amounting to 2158.26. The Price to Book ratio for the last quarter was 1.20.
ATHE Stock Performance Analysis:
Alterity Therapeutics Limited [ATHE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.22. With this latest performance, ATHE shares dropped by -12.66% in over the last four-week period, additionally sinking by -29.59% over the last 6 months – not to mention a drop of -9.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATHE stock in for the last two-week period is set at 48.63, with the RSI for the last a single of trading hit 48.60, and the three-weeks RSI is set at 48.90 for Alterity Therapeutics Limited [ATHE]. The present Moving Average for the last 50 days of trading for this stock 1.4271, while it was recorded at 1.3850 for the last single week of trading, and 1.5088 for the last 200 days.
Insight into Alterity Therapeutics Limited Fundamentals:
Return on Total Capital for ATHE is now -116.98, given the latest momentum, and Return on Invested Capital for the company is -113.53. Return on Equity for this stock declined to -113.53, with Return on Assets sitting at -90.26. When it comes to the capital structure of this company, Alterity Therapeutics Limited [ATHE] has a Total Debt to Total Equity ratio set at 0.47. Additionally, ATHE Total Debt to Total Capital is recorded at 0.47, with Total Debt to Total Assets ending up at 0.34. Long-Term Debt to Equity for the company is recorded at 0.01, with the Long-Term Debt to Total Capital now at 0.01.
Reflecting on the efficiency of the workforce at the company, Alterity Therapeutics Limited [ATHE] managed to generate an average of -$1,121,400 per employee.Alterity Therapeutics Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.30 and a Current Ratio set at 12.30.
Alterity Therapeutics Limited [ATHE] Insider Position Details
There are presently around $1 million, or 3.30% of ATHE stock, in the hands of institutional investors. The top three institutional holders of ATHE stocks are: MORGAN STANLEY with ownership of 627,907, which is approximately 7.87% of the company’s market cap and around 18.70% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 224,690 shares of the stock with an approximate value of $0.31 million in ATHE stocks shares; and VIRTU FINANCIAL LLC, currently with $96000.0 in ATHE stock with ownership of nearly New of the company’s market capitalization.
Positions in Alterity Therapeutics Limited stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 3 institutional holders increased their position in Alterity Therapeutics Limited [NASDAQ:ATHE] by around 180,726 shares. Additionally, 3 investors decreased positions by around 284,498 shares, while 6 investors held positions by with 538,923 shares. The mentioned changes placed institutional holdings at 1,004,147 shares, according to the latest SEC report filing. ATHE stock had 2 new institutional investments in for a total of 134,916 shares, while 1 institutional investors sold positions of 185,843 shares during the same period.